Manulife (Manufacturers Life Insurance)’s Inhibikase Therapeutics IKT Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio IKT Stock Details IKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$48.3K	Buy	+28,773	New	+$51.1K	﹤0.01%	2744

Other funds holding IKT

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Manulife (Manufacturers Life Insurance)'s IKT Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) opened a new position in Inhibikase Therapeutics (IKT) in Q1 2026: 28,773 shares worth $48.3K. The stake represents ﹤0.01% of the portfolio and ranks #2744 among its holdings.

104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

Manulife (Manufacturers Life Insurance) held 28,773 shares of Inhibikase Therapeutics worth $48.3K as of Q1 2026.
Inhibikase Therapeutics was a new Manulife (Manufacturers Life Insurance) position in Q1 2026.
Inhibikase Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #2744 holding.
104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.